Anti-Ma (anti-PNMA1 + PNMA2) | Anti-Ta (anti-PNMA2) | Statistical analysis | |||
n | 26 | 36 | |||
Sex (F/M) | 16/10 | 8/28 | p = 0.004 (FT) | ||
Age (y) (mean, median, range) | 61, 61, 38–82 | 44, 38, 21–81 | p = 0.001 (RST) | ||
Neurological syndromes | Cerebellar/brainstem syndrome 77%, limbic encephalitis 65%, polyneuropathy 12%, extrapyramidal symptoms 8%, myelopathy 4% | Limbic encephalitis 64%, cerebellar/brainstem syndrome 39%, extrapyramidal symptoms 6%, polyneuropathy 6%, myelopathy 3% | NS | ||
Tumour | Tumour diagnosis in 77%, thereof lung 25%, GIT 15%, breast 10%, NHL 10%, germ cell 10%, salivary gland 10%, renal rhabdoid 5%, ovary 5%, melanoma 5%, unknown primary 5% | Tumour diagnosis in 89%, thereof germ cell 75%, lung 9%, breast 9%, NHL 3%, ovary 3% | Germ cell vs non-germ cell p<0.001 (FT) | ||
Time of diagnosis of tumour | Paraneoplastic syndrome before tumour diagnosis: 66%, range 2–14 mo, paraneoplastic syndrome after tumour diagnosis: 39%, range 4 mo–14 y | Paraneoplastic syndrome before tumour diagnosis: 82%, range 2–36 mo, paraneoplastic syndrome after tumour diagnosis: 18%, range 1 mo–14 y | NS | ||
CNS imaging | Abnormal 86% | Abnormal 82% | NS | ||
CSF | Abnormal 77% | Abnormal 81% | NS | ||
Outcome (neuro) | Progression 75%, stabilisation 19%, improvement 5% | Progression 31%, stabilisation 38%, improvement 31% | Progression vs non-progression p = 0.009 (FT) | ||
Outcome (tumour) | Stabilisation 82%, progression 27% | Stabilisation 95%, progression: 5% | NS | ||
Death | 38% (thereof 70% due to neurological deterioration) | 14% (thereof 80% due to neurological deterioration) | Death vs alive p = 0.021 (FT) |
FT, Fisher’s exact test; GIT, gastrointestinal; NHL, non-Hodgkin lymphoma; RST, Mann–Whitney rank sum test.
Classification of anti-Ma and anti-Ta according to the respective publication. In some studies testing of anti-PNMA1 was not performed and hence classification as anti-Ta or anti-Ma unclear.